Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high selectivity and minimal off-target effects, potentially positioning it as a better alternative to the approved TYK2 inhibitor, Sotyktu. Despite strong midstage trial data and a solid cash runway, the highly competitive market and recent IPO status present significant investment risks.
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering
On Friday, Alumis Inc ALMS priced its initial public offering at $16/share, the low end of the range of $16 to $18, raising $210 million via 13.13 million shares offering.
Therapy developer Alumis prices U.S. IPO at about $902 mln valuation
Alumis set the pricing of its U.S. initial public offering at $16 per share, the lower end of its price range, valuing it at around $902 million.
Therapy developer Alumis seeks up to $1 bln valuation in US IPO
Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday.
Alumis eyes $300 million in proceeds in IPO
Biopharmaceutical company Alumis Inc. on Monday said it plans to offer 17.65 million shares at an estimated price range of $16 to $18 a share in its upcoming initial public offering. At the midpoint of its range, Alumis will raise about $300 million with underwriters Morgan Stanley, Leerink Partners, Cantor and Guggenheim Securities.
Alumis' $100 Million IPO: Promising Psoriasis Treatment Results
Alumis Inc. has filed for a $100 million IPO to advance its later-Phase trials treatment programs. Lead candidate ESK-001 shows positive trial results for psoriasis treatment, driving potential demand for company shares. The global psoriasis treatment market forecasted to reach $44 billion by 2031, with Alumis seeking U.S. public capital market investment.
